Features of case management with neuromuscular disease during COVID-19. Clinical impression

Features of case management with neuromuscular disease during COVID-19. Clinical impression

Alexander S. Samoylov, Olga V. Karpova, Yury D. Udalov, Roman A. Kudryavtsev

The new COVID-19 coronavirus infection, which has become a pandemic, is a very dangerous disease, the clinical picture of which can vary from mild to extremely severe forms of the course. Currently, there are no complete data on the pathogenetic mechanism of SARS-CoV-2, but there are extensive data on the probable risk factors for the development of extremely severe forms of COVID-19. The study of such factors becomes most suitable in terms of preventing their development and influence on the course of the disease in individuals with compromised immune systems and patients with impaired neuromuscular transmission. The article describes two clinical cases of extremely severe COVID-19 in patients with impaired neuromuscular transmission. Based on the analysis of the course of diseases, the conclusions are made about the possible aggravation and mutual activation of the immunopathological process with the launch of the cascade mechanism of the cytokine storm. An assumption has been made about the influence of human leukocyte antigen (HLA) on the severity of COVID-19, which is confirmed by a positive dynamics against the background of administration of IVIG, glucocorticosteroids (GCS), virusinactivated plasma and extracorporeal detoxification methods.

2020

coronavirus, Viral pneumonia, covid-19, severe disease, Myasthenia, critical illness polyneuropathy, impaired neuromuscular transmission

10.17816/clinpract34580

Клиническая практика

Eco-vector

Medicine